Since the commencement of Brexit transition timelines, the entire medical devices community is underway to understand its impact on future trade and Regulatory relations between the European Union (EU) and the United Kingdom (UK). As noted, the UK left the EU on January 31, 2020, as per the Withdrawal Agreement between both the countries.
-
October 13, 2020 Medical Devices
-
October 8, 2020 Pharmaceutical, Regulatory Affairs
It is a known fact that the UK has officially left the European Union (EU) on January 31, 2020 and it is in the transition period until December 31, 2020. During the transition period, all the pharmaceutical companies in the UK must abide by the EU pharmaceutical law.
-
September 17, 2020 Compliance, Audit and Validation, Pharmaceutical, Regulatory Affairs
Post-Brexit, the biggest challenge for the pharmaceutical industry is its potential implication on Regulatory affairs. The derogation as a result of post-Brexit is expected to hit the pharmaceutical industry extremely hard, especially the Pharma companies operating in the UK.
-
February 27, 2020 Medical Devices, Pharmaceutical
On January 31, 2020, the United Kingdom (UK) officially left the European Union (EU) making the Brexit come alive. In the light of Brexit, the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) have released certain Regulatory guidelines to ensure both pharmaceutical and medical device manufacturers are ready for the transition period.
-
January 31, 2020 Cosmetics Regulatory Services
Brexit is just around the corner and the United Kingdom (UK) is all set to leave the European Union (EU). The implementation date of Brexit was yet again postponed to January 31, 2020, after the UK requested more time for preparations.
-
October 30, 2019 Medical Devices, Regulatory Affairs
As the Brexit deadline is fast approaching, the occurrence of a no-deal Brexit is likely. In this context, the Medicines and Healthcare products Regulatory Agency (MHRA) of the UK has updated its no-deal Brexit guidance on the regulation of medicines, medical devices, and respective clinical trials.
-
August 28, 2019 Cosmetics Regulatory Services, Regulatory Affairs
Though scheduled to take place from March 29, 2019, the Brexit has now postponed to October 31, 2019. The decision is assumed to give more time to the United Kingdom (UK) and the European Union (EU) to agree upon the terms of the UK leaving the EU.
-
March 4, 2019 Pharmaceutical, Regulatory Artwork Services, Regulatory Affairs
The impact of Brexit is evident in almost every industry based in the European Union (EU) and the United Kingdom (UK). Pharmaceutical industry too not to be spared.
-
February 18, 2019 Publishing & Submissions
The impact of Brexit has been a major topic for debates amongst the industry experts for the past two years. It has left companies on both the sides, the United Kingdom (UK) and Europe, hanging on a loose thread. As the date of Brexit is drawing closer, industries are aggressively looking for contingency plans for sustaining their business, if the UK leaves with a ‘no-deal’.
-
January 7, 2019 Pharmaceutical, Medical Devices, Food and Food Supplements, Regulatory Affairs
With each year, Life Sciences industry is transforming in unpredictable ways, of course it is to better the end-user’s safety. The industry is progressing with technological advancements and the health authorities are equally striving to upgrade the existing Regulatory frameworks to align with market requirements.